Kennedy Ferruggia, Associate Editor

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

Pharmacists can continue to spread awareness of the importance of receiving a shingles vaccine.

Increasing vaccine coverage among adults at highest risk could lessen associated hospitalizations and severe outcomes caused by RSV.

Use of antitherapeutic medication prescribed for herpes zoster related to lower risk of subsequent dementia.

RSV vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults.

White button mushroom can rebuild anti-cancer immune defense while slowing cancer growth.

Researchers applied extracellular vesicles retrieved from human red blood cells to serve as natural carrier to deliver the anti-cancer antisense oligonucleotides to the tumor site.

LBL-034 could be best in class in treating individuals with multiple myeloma.

Vitamin K2 displayed a marked reduction in cramp frequency compared to a placebo.

Brivudine is more effective in treating herpes zoster and does not increase the risk of adverse reactions.

RSV vaccines were 80% effective in preventing hospitalization, ICU admission, and death among adults aged 60 years and older.

Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory infection hospitalizations by more than 84% and 90% in preterm and full-term infants, respectively.

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

The randomized, placebo-controlled RESCUE phase 3 trial assessed clofutriben among individuals with ACTH-dependent endogenous Cushing syndrome.

Low levels of vitamin D was linked with increased obstructive Apnea-Hypopnea Index scores.

Further efforts may be required to urge eligible members of the public to get screened for lung cancer.

Findings suggest further need to educate the public on receiving an indicated vaccine as we approach peak respiratory syncytial virus (RSV) season.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

Findings highlight the need for health care providers to continue to educate patients on the risk of scurvy, ensuring proper vitamin C intake.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

The connection of F proteins could help destabilize the virus prior to infection of the next host.

Increasing serum vitamin B12 before and after the onset of pancreatitis reduced the severity of the condition.

The results emphasize the need for pharmacists and health care providers to further educate patients about receiving recommended immunizations.

Gepotidacin could be first-in-class oral antibiotic treatment approved for uUTIs in over 20 years.

The trial met its primary endpoint of event-free survival, furthering treatment options for resected, locally advanced head and neck squamous cell carcinoma.